Preventing postsurgical colorectal cancer relapse: A hemostatic hydrogel loaded with METTL3 inhibitor for CAR-NK cell therapy
Source abstract
Abstract
Colorectal cancer (CRC) recurrence post-surgery remains a major challenge. While Chimeric Antigen Receptor (CAR)-engineered natural killer (NK) cells hold immense therapeutic potential, their intratumoral infiltration ability remains limited, hampering efficacy. Building upon prior research suggesting that chemokines like C-X-C motif chemokine ligand 9 (CXCL9) and C-X-C motif chemokine ligand 10 (CXCL10) recruit CAR-NK cells, we hypothesized that tumor cell m6A methylation, regulated by Methyltransferase-like 3 (METTL3), influences chemokine secretion. This study aims to elucidate the underlying mechanisms and improve METTL3 inhibition efficiency. We designed an adhesive hemostasis hydrogel loaded with STM2457, a METTL3 inhibitor, aimed at sustained release in the acidic tumor microenvironment. In vitro, the hydrogel promoted CAR-NK cell recruitment and tumor killing via sustained METTL3 inhibition. The hydrogel's Schiff base bonds further enabled intestinal adhesion and hemostasis in an incomplete tumor resection model of CRC. Combining the hydrogel with CAR-NK cell therapy significantly reduced CRC recurrence in vivo. Overall, our study reveals the crucial role of METTL3 in CRC recurrence and proposes a promising, multimodal strategy using STM2457-loaded hydrogel and CAR-NK cells for enhanced therapeutic efficacy. This schematic illustrates the process of preparing GOSM-gel and the combination therapy strategy involving tumor excision, GOSM-gel administration, and CAR-NK cells injection for CRC. GOSM-gel, injected at the tumor resection site margin, forms an adhesive gel at the targeted location. The in-situ production of the hydrogel is triggered by the upregulation of CXCL9 and CXCL10 through the downregulation of METTL3, enhancing the therapeutic efficacy of CAR-NK cells infusion. • An in situ injection hydrogel for colorectal cancer after resection was developed. • The gel has excellent adhesive and hemostatic properties for clinical application. • The gel can regulate m6A methylation and accumulate CAR-NK cells to kill cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immune Cell Function and Interaction · Cancer Research and Treatments · Cancer Cells and Metastasis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries10.3322/caac.21660 ↗
2. Management of colorectal cancer
3. Association between intensity of posttreatment surveillance testing and detection of recurrence in patients with colorectal cancer10.1001/jama.2018.5816 ↗
4. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer10.1038/s41591-022-02115-4 ↗
5. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making10.1093/annonc/mds236 ↗
6. Colorectal cancer
7. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer10.1158/2159-8290.CD-20-0556 ↗
8. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients10.1016/j.ymthe.2019.03.011 ↗
9. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy10.1186/s13045-021-01083-5 ↗
10. Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells10.1016/j.stemcr.2014.01.014 ↗
11. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity10.1016/j.stem.2018.06.002 ↗
12. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia10.1126/scitranslmed.aaf2341 ↗
13. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities10.1136/jitc-2021-003894 ↗
14. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma10.1038/s41408-021-00537-w ↗
15. Prognostic significance of tumor-infiltrating natural killer cells in solid tumors: a systematic review and meta-analysis10.3389/fimmu.2020.01242 ↗
16. IFN-Γ: a cytokine at the right time, is in the right place10.1016/j.smim.2019.05.002 ↗
17. m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy10.15252/embj.2020104514 ↗
18. Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer10.1186/s13045-020-00895-1 ↗
19. The role, mechanism, and application of RNA methyltransferase METTL14 in gastrointestinal cancer10.1186/s12943-022-01634-5 ↗
20. Progress and prospect of nanotechnology for cardiac fibrosis treatment
21. Tumor-microenvironment-activatable polymer nano-immunomodulator for precision cancer photoimmunotherapy
22. Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper combined with αpd-L1 for enhanced cancer immunotherapy10.1002/adma.202370152 ↗
23. Engineering multifunctional adhesive hydrogel patches for biomedical applications
24. A physiologically responsive nanocomposite hydrogel for treatment of head and neck squamous cell carcinoma via proteolysis-targeting chimeras enhanced immunotherapy
25. An injectable epigenetic autophagic modulatory hydrogel for boosting umbilical cord blood NK cell therapy prevents postsurgical relapse of triple-negative breast cancer
26. Injectable adhesive hemostatic gel with tumor acidity neutralizer and neutrophil extracellular traps lyase for enhancing adoptive NK cell therapy prevents post-resection recurrence of hepatocellular carcinoma10.1016/j.biomaterials.2022.121506 ↗
27. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy10.1186/s13287-021-02251-7 ↗
28. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy10.5966/sctm.2012-0084 ↗
29. A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies10.1038/nprot.2008.42 ↗
30. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein10.1182/blood-2013-10-532531 ↗
31. Hematopoietic and nature killer cell development from human pluripotent stem cells10.1007/978-1-62703-478-4_3 ↗
32. Hybrid gelatin/oxidized chondroitin sulfate hydrogels incorporating bioactive glass nanoparticles with enhanced mechanical properties, mineralization, and osteogenic differentiation
33. Injectable self-healing natural biopolymer-based hydrogel adhesive with thermoresponsive reversible adhesion for minimally invasive surgery
34. An integrated strategy for rapid hemostasis during tumor resection and prevention of postoperative tumor recurrence of hepatocellular carcinoma by antibacterial shape memory cryogel10.1002/smll.202101356 ↗
35. An adhesive hydrogel with “load-sharing” effect as tissue bandages for drug and cell delivery10.1002/adma.202001628 ↗
36. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses10.1126/sciadv.aaz4204 ↗
37. Gelatin methacryloyl hydrogels control the localized delivery of albumin-bound paclitaxel10.3390/polym12020501 ↗
38. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia10.1038/s41586-021-03536-w ↗
39. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy., Cell Reports
40. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy10.1038/aps.2017.125 ↗
41. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues10.1006/scbi.1998.0119 ↗
42. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice
43. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors10.1158/1078-0432.CCR-15-1696 ↗
44. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma10.1186/s12943-019-1038-7 ↗
45. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis10.1186/s13046-021-02227-8 ↗
46. RNA N(6)-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m(6)A-GLUT1-mTORC1 Axis and is a therapeutic target10.1053/j.gastro.2020.11.013 ↗
47. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway10.1186/s13046-019-1408-4 ↗
48. pH-Responsive nanoparticles based on cholesterol/imidazole modified oxidized-starch for targeted anticancer drug delivery10.1016/j.carbpol.2020.115858 ↗
49. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m(6)A-YTHDF2-dependent manner10.1038/s41388-022-02185-1 ↗
50. METTL3 regulates m(6)A methylation of PTCH1 and GLI2 in Sonic hedgehog signaling to promote tumor progression in SHH-medulloblastoma10.1016/j.celrep.2022.111530 ↗
51. METTL3 inhibits antitumor immunity by targeting m(6)a-BHLHE41-CXCL1/CXCR2 Axis to promote colorectal cancer10.1053/j.gastro.2022.06.024 ↗
52. Biopolymer immune implants' sequential activation of innate and adaptive immunity for colorectal cancer postoperative immunotherapy10.1002/adma.202004559 ↗
53. In–situ-sprayed dual-functional immunotherapeutic gel for colorectal cancer postsurgical treatment10.1002/adhm.202100862 ↗